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Atherosclerosis is a systemic disease that aﬀects most vascular beds. The gold standard of atherosclerosis imaging has been
invasive intravascular ultrasound (IVUS). Newer noninvasive imaging modalities like B-mode ultrasound, cardiac computed
tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI) have been used to assess these
vascular territories with high accuracy and reproducibility. These imaging modalities have lately been used for the assessment
of the atherosclerotic plaque and the response of its volume to several medical therapies used in the treatment of patients
with cardiovascular disease. To study the impact of these medications on atheroma volume progression or regression, imaging
modalitieshavebeenusedonaserialbasisprovidingauniqueopportunitytomonitortheeﬀecttheseantiatheroscleroticstrategies
exertonplaqueburden.Asaresult,studiesincorporatingserialIVUSimaging,quantitativecoronaryangiography(QCA),B-mode
ultrasound, electron beam computed tomography (EBCT), and dynamic contrast-enhanced magnetic resonance imaging have all
beenusedtoevaluatetheimpactoftherapeuticstrategiesthatmodifycholesterolandbloodpressureontheprogression/regression
of atherosclerotic plaque. In this review, we intend to summarize the impact of diﬀerent therapies aimed at halting the progression
or even result in regression of atherosclerotic cardiovascular disease evaluated by diﬀerent imaging modalities.
1.Introduction
Atherosclerosis is a systemic disease that can aﬀect multiple
vascular beds and is associated with signiﬁcant mortality
and morbidity. There is an increased interest in the car-
diovascular (CV) community in studying the impact of
medical therapy on the progression or even the regression of
atheroma volume and extent. Change in atheroma volume
in response to novel therapies is an attractive “surrogate
endpoint” for clinical cardiovascular events as it reﬂects
the pathophysiology of the underlying disease, and oﬀers
a more economically feasible approach to test eﬃcacy with
fewer patients and resources, and over a shorter follow-up
duration [1]. The usual hard and soft clinical endpoints
have economic and logistical implications [2] and thus CV
researchershavealwaysbeeneagertoidentifyothersurrogate
endpoints that would correlate with improvement in clinical
outcomes. The enthusiasm for measuring plaque volume
is also because increments in the size of atherosclerotic
plaque correlate with major adverse cardiovascular events
(MACE) [3, 4]. Such observations have fueled eﬀorts
at studying medications that target plaque regression or
decrease progression early on in patients with atherosclerotic
coronary artery disease (CAD). This is based on the premise
that a favorable eﬀect of novel therapies on atherosclerotic
plaque volume would translate into a favorable clinical
eﬀect, and help eﬃciently triage novel therapies from the
laboratory bench to the bedside. This process has been
facilitated by the development of new imaging techniques
that can assess atherosclerotic plaque. A number of imaging
modalities that visualize the arterial wall provide a unique
opportunity to characterize the impact of potential anti-
atherosclerotic therapies in the in vivo setting. Herein,
we provide a review of medications that target plaque
volume2 Cardiology Research and Practice
2. Therapies That Target Atheroma Volume
2.1. The Eﬀects of Antihypertensive Agents (Table 1)
2.1.1. Calcium Channel Blockers. The potential eﬀect of
calcium channel blockers on atherosclerosis has been studied
more than 20 years ago. The “regressive” eﬀects of nicardip-
ine and nifedipine on atherosclerosis in cholesterol-fed mice
were observed after 8 weeks of treatment by a reduction in
aortic arch plaque area and cholesterol accumulation [5].
Waters et al. [6] in 1992 found that nicardipine had no
eﬀect on angiographically detected advanced atherosclerosis
but may halt the progression of minimal lesions through
its antihypertensive eﬀects. Several clinical trials [7–11] that
studied the anti-atherosclerotic eﬀects of calcium channel
blockers showed regression of carotid intima-media thick-
ness detected by B-mode ultrasonography. The Prospective
Randomized Evaluation of the Vascular Eﬀects of Norvasc
Trial (PREVENT) [9] randomized 825 patients with nonob-
structive CAD to amlodipine versus placebo. At the end of
the follow-up period, the progression and development of
new atherosclerotic lesions detected by quantitative coronary
angiography were similar in the two groups (−0.084mm
versus −0.095mm, P=.38). In the same trial, a subset
of patients (n=377), had regression/stabilization of CIMT
detected by high resolution B-mode carotid ultrasonography
in the amlodipine group, while progression was uninter-
rupted in the placebo group (−0.013mm versus +0.033mm,
P=.007). The mechanism of amlodipine-associated slowing
of the progression of intima-media thickness may be related
to its antihypertensive eﬀect, as well as to its eﬀect on cellular
growth and hyperplasia of the arterial wall. Likewise, on the
otherhand,theCoronaryAngioPlastyAmlodipineRESteno-
sis Study (CAPARES) [12] investigated the eﬀect of amlodip-
ine versus placebo on minimal luminal diameter detected
by quantitative coronary angiography in patients with stable
angina pectoris undergoing percutaneous coronary angio-
plasty. The trial showed that treatment with amplodpine
did not aﬀect minimal luminal diameter assessed by quan-
titative coronary angiography (−0.30 ± 0.45mm versus
−0.29 ± 0.49mm; P=.84) after a four-month period. How-
ever, the study showed that the incidence of repeat percu-
taenous coronary intervention and MACE were signiﬁcantly
lower in patients treated with amlodipine. Similarly, the
IVUS-based trial, Comparison of Amlodipine and Enalapril
to Limit Occurrence of Thromobosis (CAMELOT) and
Norvasc for Regression of Manifest Atherosclerotic Lesions
by Intravascular Sonographic Evaluation (NORMALISE)
[13, 14] showed a signiﬁcant reduction in MACE with
amlodipine but not with enalapril or placebo. This ﬁnding
however, did not project to the same extent in the coronary
arteries. The percent atheroma volume measured by IVUS
in 274 patients was relatively unchanged in the amlodipine
group (+0.5 ± 3.9%; P=.31), and increased somewhat in
the enalapril group, (+0.8 ± 3.7%; P=.08), and signiﬁcantly
in the placebo group (+1.3 ± 4.4%; P=.001) (all numbers
reﬂect percent change in atheroma volume from baseline
after a 24 month period). There was no statistical diﬀerence
in percent change in atheroma volume across groups.
2.1.2. Angiotensin Converting Enzyme Inhibitors and
Angiotensin II Receptor Blockers. The Prevention of
Atherosclerosis with Ramipril (PART-2) Collaborative
Research Group [15] examined the anti-atherosclerotic
eﬀect of ramipril (5–10mg/d) or placebo in 617 patients
with coronary or other occlusive arterial disease. B-mode
ultrasonography revealed no structural diﬀerence between
groups in changes in common carotid artery-wall thickness
or in carotid plaque score at 2 and 4 years with a trend
toward a beneﬁt in death from cardiovascular events.
The Study to Evaluate Carotid Ultrasound changes with
Ramipril and Vitamin E (SECURE) [16], a substudy
of the Heart Outcomes Prevention Evaluation (HOPE)
trial, used B-mode carotid ultrasonography to monitor
atherosclerotic lesions in patients aged 55 years or older
with vascular disease or diabetes and at least one other
risk factor. Ramipril reduced carotid artery atherosclerosis
progression rates, as measured by intimal medial thickness.
In a quantitative coronary angiography substudy of 450
randomly selected patients from the Quinapril Ischemic
Event Trial (QUIET), quinapril did not diﬀer from placebo
in progression of coronary atherosclerosis, new stenosis
development, change in minimum lumen diameter index,
or change in percent diameter stenosis index [17]. Similar
results were obtained from another quantitative coronary
angiography study, the Simvastatin/Enalapril Coronary
Atherosclerosis Trial (SCAT) [18], where Enalapril failed
to show regression in atheroma volume, but showed a
signiﬁcantly lower combined endpoint of death/myocardial
infarction/stroke than placebo.
Theanti-atheroscleroticeﬀectsofAngiotensinIIreceptor
blockers (ARB) were elucidated in animal models [19].
The MORE study [20] used 2D-ultrasound to assess the
changes in common carotid intima-media thickness in
hypertensive patients treated with olmesartan. Olmesar-
tan signiﬁcantly reduced the atheroma volume of larger
(>33.7μL) atherosclerotic plaques compared with atenolol
(−11.5 ± 4.4μLv e r s u s+ 0 . 6±2.5μL; P=.023). The eﬀect of
ARB on atheroma volume in coronary arteries was studied
in 64 patients with nonocclusive left main CAD [21]. Serial
IVUS studies were performed at baseline and after 7-month
follow-up. In the ARB group, vessel volume index signif-
icantly decreased during follow-up (9.9±3.1mm2 versus
9.1 ± 2.7mm2; P<.01). These clinical trials suggest that
ARB could cause regression of atherosclerosis in the vascular
beds of humans.
2.1.3. β-Adrenergic Receptor Blockers. β-Adrenergic receptor
blockers reduce recurrent myocardial infarction, sudden
cardiac death, and all cause mortality in patients after
myocardial infarction [22–25]. To study the eﬀect of Beta-
Blocking agents on the progression of atherosclerosis, Sipahi
et al. [26] conducted a post-hoc, pooled analysis of indi-
vidual patient data from 4 intravascular ultrasonography
(IVUS) trials: Reversal of Atherosclerosis with Aggres-
sive Lipid Lowering (REVERSAL) [14], Acyl-CoA: Choles-
terol Acyltransferase Intravascular Atherosclerosis Treatment
Evaluation (ACTIVATE) [27], A Study to Evaluate the EﬀectCardiology Research and Practice 3
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of Rosuvastatin On Intravascular Ultrasound (ASTEROID)
[28], and CAMELOT/NORMALISE [13, 29]. The latter
trial was described above and compared the eﬀects of
amlodipine to Enlapril and placebo in reducing atheroma
volume. The REVERSAL study evaluated the eﬀects of mod-
erate versus intensive lipid-lowering therapy with statins.
ACTIVATE evaluated the eﬀect of the acyl coenzyme A
(CoA)—cholesterol acyltransferase inhibitor pactimibe, and
ASTEROID evaluated the eﬀect of very-high-intensity lipid-
loweringtherapywithrosuvastatinontheprogressionrateof
coronary atherosclerosis. This pooled analysis of individual
datafrom1515patientsenrolledinthese4trialsandfollowed
up for 18 to 24 months revealed that atheroma volume
decreased signiﬁcantly in patients receiving β-blockers com-
pared to those who did not (−2.4 ± 0.5mm3/yr versus
−0.4 ± 0.8mm3/yr; P=.034).
2.1.4. Mineralocorticoid Hormones. Mineralocorticoid hor-
mones play an important role in endothelial dysfunction,
vascular ﬁbrosis, and inﬂammation in the vasculature, and
is involved in the pathogenesis of hypertension [30, 31].
Takaietal.studiedtheanti-atheroscleroticeﬀectsofthemin-
eralocorticoid receptor blocker, eplerenone, in nonhuman
primates fed a high cholesterol diet [32]. IVUS analysis of
the thoracic aorta revealed that the ratio of intimal volume
to total volume was signiﬁcantly lower in a dose-dependent
manner in the eplerenone-treated groups. This positive
ﬁnding in nonhuman primates has not been validated in
human vascular beds.
2.2. Therapies That Target Cholesterol (Table 2)
2.2.1. Statins, Niacin, Ezetimibe, Fibrates, and Colestipol.
The direct relation between serum LDL-cholesterol and
HDL-cholesterol versus serial changes in coronary plaque
dimensions was elucidated in the study by Von Birgelen et
al. [33]. Standard IVUS analysis of 60 left-main coronary
arteries obtained 18 months apart revealed a positive linear
relationship between LDL-cholesterol and annual changes in
plaque size. An LDL cholesterol cut-oﬀ value of 75mg/dl
was found at which there was no increase in atheroma
cross-sectional area. Furthermore, HDL-cholesterol levels
had an inverse relationship with changes in plaque size. This
correlation between lipoprotein levels and atheroma volume
progression/regression pushed cardiovascular researchers to
studytheeﬀectsofserumlipidmodiﬁcationonangiographic
endpoints.
The cholesterol lowering atherosclerosis study (CLAS)
[34] evaluated the eﬀect of lipid lowering on structural
angiographic endpoints in 162 patients and correlated
these outcomes with functional clinical endpoints. The
atheroma volume assessed after 2 years of treatment
with niacin/colestipol by global change score (GCS) and
quantitative coronary angiography revealed the following
by GCS (drug versus placebo): regression (16% versus
4%), no change (45% versus 37%), and progression (39%
versus 59%) (P=.004) and a signiﬁcant improvement in
percent stenosis (0.3 ± 5.9% versus 2.7 ± 5.8%; P=.02)
and minimum lumen diameter (−0.01 ± 0.22mm versus
−0.09 ± 0.26mm; P=.04) detected by quantitative coro-
nary angiography. The same Simvastatin/Enalapril Coro-
nary Atherosclerosis Trial (SCAT) [18], mentioned above,
evaluated the anti-atherosclerotic eﬀects of statins in 394
normocholesterolemic patients over 4 years. Patients taking
simvastatin had less progression in their atherosclerotic
lesions, highlighted by a 1.67% change in percent diameter
stenosis in the simvastatin group versus 3.83% in the
placebo group; P=.0003 detected by quantitative coro-
nary angiography and less often required percutaneaous
coronary intervention during the study period. The anti-
atherosclerotic eﬀect of Simvastatin/niacin in patients with
low HDL and normal LDL cholesterol was evaluated in 160
patients randomized to 1 of 4 treatment arms by Brown
et al. [35]. Coronary angiography repeated after 3 years of
therapy showed regression in percent stenosis in proximal
coronary arteries in the simvastatin/niacin group compared
to placebo (0.4% decrease versus 3.9% increase, P<.001).
This structural beneﬁt detected on follow-up angiography
translated into a lower MACE rate (3% versus 24%, P=.04).
The REVERSAL trial [14] studied the structural eﬀects
of intensive lipid lowering therapy with 80mg atorvastatin
versus moderate lipid lowering with 40mg pravastatin.
The baseline LDL-cholesterol was reduced to 110mg/dL in
the pravastatin group and to 79mg/dL in the atorvastatin
group(P<.001).Thepercentagechangeinatheromavolume
from baseline measured in 654 patients with high LDL
(mean150.2mg/dL)andangiographicCAD(>20%stenosis)
was signiﬁcantly lower in the atorvastatin group, P=.02.
Atheroma volume increased in the moderate lipid-lowering
arm (pravastatin 40mg) by a mean of 2.4% (95% CI
0.2%–4.7%, P=.001) and remained almost the same in
the atorvastatin group after an 18-month follow-up (mean
decrease by 0.4%, 95% CI −2.4%–1.5%, P=.98).
Other studies demonstrated that LDL-cholesterol low-
ering with statins could reverse angiographically detected
CAD. In the ESTABLISH study, Okazaki et al. [36]a n a -
lyzed the impact of 20mg of atorvastatin on nonculprit
lesions in patients with acute coronary syndrome by serial
IVUS. Plaque volume was signiﬁcantly reduced in the
atorvastatin group (13.1 ± 12.8% decrease) compared with
the control group (8.7 ± 14.9% increase; P<.0001). This
structural change correlated with a signiﬁcant decrease
(41.7%, P<.0001) in LDL-cholesterol level by lipid-lowering
therapy for 6 months (r =0.612, P<.0001). The Low-
density Lipopoprotein Apheresis Coronary Morphology and
Reserve Trial (LACMART) [37] conducted in patients with
familial hypercholesterolemia evaluated the eﬀects of LDL-
cholesterol lowering with apheresis on atheroma volume. At
one-year follow-up, the medication+LDL-Apheresis (LDL-
A) group showed 28.4% reduction in total cholesterol
and 34.3% reduction in LDL cholesterol after one-year
follow-up, while the medication alone group showed no
changes in cholesterol levels. IVUS evaluation at 1 year
showed a decrease in plaque area (baseline: 8.45 ± 4.22mm2
versus 1yr: 7.76 ± 4.34mm2), and an increase in mini-
mal lumen diameter (baseline: 1.99 ± 0.73mm versus 1yr:
2.11 ± 0.81mm) from study outset in the LDL-A groupCardiology Research and Practice 5
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and a reverse result ((baseline plaque area: 7.19 ± 2.88mm2
versus 1yr plaque area: 8.08 ± 3.14mm2); (baseline MLD:
2.24 ± 0.89mm versus 1yr MLD: 2.16 ± 0.84mm)) in the
medication only group (P=.008 and.017 for change in
plaque area and change in MLD, resp.). Similarly positive
results were recently observed in A Study to Evaluate the
Eﬀect of Rosuvastatin on Intravascular Ultrasound-Derived
Coronary Atheroma Burden (ASTEROID) [28]. Intensive
lipid lowering with 40mg Rosuvastatin in the 349 patients
(69%) who had 24-month follow-up [38] caused a decrease
in LDL cholesterol by 53.4% and an increase in HDL
cholesterol by 14.6% from baseline. Median reduction of
total atheroma volume from baseline was 6.8% (P<.001)
after 24 months of intensive treatment by rosuvastatin.
The eﬀect of lipid lowering therapy on plaque compo-
sition was highlighted in another study that compared the
eﬀect of 20mg atorvastatin versus usual care among patients
with coronary artery disease [39]. At 12-month follow-up
plaque volume and plaque echogenicity was assessed by
IVUS.Meanabsoluteplaquevolumeshowedalargerincrease
in the usual care group compared with the atorvastatin
group (9.6 ± 28.1 and 1.2 ± 30.4, resp.; P=.191). The
hyperechogenicity index, a marker of plaque composition,
increased to a larger extent for the atorvastatin group than
for the usual care group, with a signiﬁcant treatment eﬀect
forthepercentchange(atorvastatin42.2%,usualcare10.1%;
P=.021).
The Ezetimibe and Simvastatin in Hypercholesterolemia
Enhances Atherosclerosis Regression (ENHANCE) trial
[40] evaluating the role of 80mg of simvastatin with or
without 10mg of Ezetimibe in 720 patients with familial
hypercholesterolemia revealed that combination therapy
did not result in a signiﬁcant reduction in CIMT after 24
months of therapy (Simvastatin only: 0.0058 ± 0.0037mm
versus 0.0111 ± 0.0038mm in the simvastatin-plus-
ezetimibe; P=.29). Another more recent 3-year trial, Stop
Atherosclerosis in Native Diabetics Study (SANDS) [41],
compared the eﬀect of standard therapy with lifestyle
modiﬁcation ± Simvastatin to attain conventional goals
for LDL-C (100mg/dl), non–HDL-C (130mg/dL), and
SBP (130mmHg), to aggressive therapy with lifestyle
modiﬁcation ± Simvastatin ± Ezetimibe to achieve goals
of 70mg/dL, 100mg/dL, and 115mmHg, respectively. By
the end of the 3-year period, the CIMT progressed in the
standard therapy group (+0.039mm) and regressed in the
aggressive therapy group (−0.025mm in ezetimibe plus
statin versus −0.012mm in nonezetimibe group), P=.0001.
There was no additional beneﬁt of adding Ezetimibe to
Simvastatin on CIMT regression in patients who achieved
their target LDL-C. Measuring Eﬀects on Intima-Media
Thickness: An Evaluation of Rosuvastatin (METEOR) study
[42], the largest placebo-controlled statin trial evaluating
the eﬀects of Rosuvastatin on CIMT in low risk patients
(10-yearFraminghamrisk score<10%),showeda signiﬁcant
regression in CIMT compared to placebo (−0.0014 versus
0.0131mm/yr; P<.001) which failed to reﬂect on a
positive clinical cardiovascular outcome. Another intriguing
unpublished 1-year clinical trial, the CASHMERE (Carotid
Atorvastatin Study in Hyperlipidemic Postmenopausal
Women: a Randomised Evaluation of Atorvastatin versus
Placebo), evaluating the eﬀe c to f8 0 m go fa t o r v a s t a t i n
comparedtoplaceboin 399post-menopausal women,found
no statistical diﬀerence in CIMT results. These inconsistent
results correlating CIMT with clinical outcomes were a
subject of debate lately questioning the patient population
being studied or the technique used in measuring CIMT.
The ARBITER 6-HALTS trial [43] is a more recent con-
troversial study presented at the American Heart Association
late breaking trials sessions in 2009 comparing the eﬀects of
extended-release niacin to ezetimibe on CIMT progression
after 8 and 14 months of treatment in 208 patients at high
risk for atherosclerotic vascular disease with LDL-cholesterol
levels (<100mg/dL) and a moderately reduced HDL level
(<42mg/dL). This study showed Niacin to be superior to
ezetimibe in aﬀecting the regression of mean and maximal
CIMT both at 8 and 14 months of treatment. Besides, niacin
showed a progressive regression in CIMT from 8 to 14
months.
2.2.2. Fibrates. The eﬀect of Fibrate use on the changes in
atheromavolumehasbeenhighlightedinafewclinicaltrials.
Fenoﬁbrate use in well-controlled diabetics has been shown
in the Diabetes Atherosclerosis Intervention Study (DAIS)
[44] to slow the progression of coronary atherosclerosis
comparedtoplaceboovera3-yearperiod,measuredbyQCA
(decrease in minimum lumen diameter (−0.06±0.016mm
versus −0.10±0.016mm, P=.029), without a signiﬁcant
improvementincardiovascularendpoints.IntheFenoﬁbrate
Intervention and Event Lowering in Diabetes (FIELD) study
[45], Fenoﬁbrate use for 5 years in patients with type-
2 diabetes was not associated with an improvement in
mean CIMT throughout the study period, P=.987. Another
study [46] comparing the eﬀect of Fenoﬁbrate on top
of antihypertensive therapy to antihypertensive treatment
alone on CIMT demonstrated some improvements after
24 months of therapy. CIMT remained the same in both
treatment groups, with a signiﬁcant improvement in CIMT
to carotid artery Diameter ratio (CIMT/D) (12.98±2.62
versus 12.12±2.26%), P<.05] in the fenoﬁbrate group. This
beneﬁcial eﬀect translated into a lower incidence of stroke in
the fenoﬁbrate intervention group (11.30% versus 21.82%;
P<.05). The St. Mary’s Ealing, Northwick Park Diabetes
Cardiovascular Disease Prevention (SENDCAP) Study [47],
studied the eﬀect of a 3-year treatment with Bezaﬁbrate on
top of usual Diabetes care compared to placebo on CIMT
and deﬁnite coronary heart disease (CHD). Bezaﬁbrate
was not associated with improvements in CIMT versus
placebo (change in CIMT 0.06±0.38. versus 0.02±0.41,
P=.5). However, there was a signiﬁcantly lower 3-year
cumulative incidence rate of deﬁnite adverse CHD event in
the bezaﬁbrate treated group than in the placebo group (7
versus 23%, P=.01log-rank test).
2.2.3. Acyl-CoA: Cholesterol Acyltransferase (ACAT)
Inhibitors. Two forms of ACAT have been identiﬁed.
ACAT1 is found predominantly in macrophages, and ACAT2
is present in the liver and in the intestinal mucosa. Inhibition8 Cardiology Research and Practice
of ACAT1 is intended to make more free cholesterol available
for reverse cholesterol transport, which, theoretically, could
reduce lipid accumulation within atherosclerotic lesions and
potentially inﬂuence progression of CAD. To evaluate the
eﬀect of ACAT inhibition on human coronary arteries, the
ACAT Intravascular Atherosclerosis Treatment Evaluation
(ACTIVATE) [48] enrolled 534 patients with symptomatic
angiographically documented CAD and performed outset
IVUS. Patients received usual care for secondary prevention,
including statins. Patients were randomly assigned to receive
the ACAT inhibitor pactimibe (100mg per day) or matching
placebo. The change in percent atheroma volume in 408
patients who completed the study at 18 months [27]w a s
similar in the pactimibe and placebo groups (0.69 percent
and 0.59 percent, resp.; P=.77). However, the total atheroma
volume showed signiﬁcant regression in the placebo group
(−5.6mm3, P=.001) but not in the pactimibe group
(−1.3mm3, P=.39); P=.03 for the comparison between
groups. The combined incidence of adverse cardiovascular
outcomes was similar in the two groups (P=.53).
A similar result was obtained with the ACAT inhibitor
avasimibe. In the Avasimibe and Progression of coronary
Lesions assessed by intravascular UltraSound (A-PLUS)
clinical trial [49, 50], IVUS and coronary angiography were
performed at baseline and repeated after up to 24 months
of treatment. Approximately equal percentages of patients
across groups (placebo, 50mg, 250mg, and 750mg of
avasimibe) received concurrent statin therapy (87% to 89%).
Percent atheroma volume increased by 0.4% with placebo
and by 0.7%, 0.8%, and 1.0% in the respective avasimibe
groups (P=NS). LDL cholesterol increased during the study
by 1.7% with placebo but by 7.8%, 9.1%, and 10.9% in
the respective avasimibe groups (P<. 0 5i na l lg r o u p s ) .
T h en e g a t i v ee ﬀect of ACAT inhibitors on atherosclerosis
progression was demonstrated in the terminated Familial
hypercholesterolemia CIMT trial, the CAPTIVATE (Eﬃcacy
and Safety of the ACAT Inhibitor CS-505 [Pactimibe] for
Reducing the Progression of Carotid Artery Disease) study,
the group on statin alone had 3.4% CVD events compared
with 6.3% (P=.02) in those on statin plus the ACAT
inhibitor pactimibe. The primary and secondary CIMT end
points were all consistent with worsening of atherosclerosis
with pactimibe.
2.2.4. Apo A-1 Milano. Apo A-1 is the major apolipoprotein
component of HDL. Patients with Apo A-1 Milano mutation
(cysteine for arginine at position 173), identiﬁed from rural
Italy, characteristically have very low HDL cholesterol and
high triglyceride levels. Paradoxically, these patients have
no evidence of CAD. The infusion of Apo A-1 Milano-
phospholipid complex signiﬁcantly reduced intimal thick-
ening and macrophage content in cholesterol fed rabbits
[51]. This intervention was replicated in patients with
ACS where the anti-atherosclerotic eﬀect of intravenous
recombinantApoA-IMilano/phospholipidcomplexes(ETC-
216) onatheromaburdenwasassessed[52].ETC-216 weekly
infusion for 5 weeks resulted in a decrement in mean
percentage atheroma volume in the ETC-216 group and
increased in the placebo group (−1.06%±3.17%; P =.02
from baseline and +0.14%±3.09%; P=.97 from baseline,
resp.).
2.2.5. Direct Lipoprotein-Associated Phospholipase A2
Inhibitor (Darapladib). The presence of inﬂammatory cells
and markers in the cap of atherosclerotic plaque correlates
with increased risk of plaque rupture [53] and subsequent
clinical events. Lipoprotein-associated phospholipase A2
is a hydrolytic enzyme that may play a role in membrane
bound LDL modiﬁcation [54]. A recent trial [55] showed
lipoprotein-associated phospholipase A2 to be a novel risk
factor independent of markers of inﬂammation or classic
risk factors. An IVUS-based study conducted recently
in 330 patients with angiographically documented CAD
comparing the eﬀects of the direct lipoprotein-associated
phospholipase A2 inhibitor (Darapladib) to placebo
showed that necrotic core volume measured by IVUS-
radiofrequency (RF) increased signiﬁcantly (4.5±17.9mm3;
P=.009) in the control group, whereas active treatment with
160mg of darapladib for 12 months halted this increase
(−0.5±13.9mm3; P=.71), (diﬀerence of −5.2mm3
between groups; P=.012). These intraplaque compositional
changes occurred without a signiﬁcant treatment diﬀerence
in total atheroma volume measured by conventional IVUS
(P=.95).
2.3. Antioxidants (Table 3). Oxygen-free radicals can stimu-
late smooth muscle cells to proliferate and maybe induce in-
stent restenosis after balloon angioplasty. Some antioxidant
agents such as vitamins, probucol, and AGI-1067 were
studied with varying anti-atherosclerotic eﬀects.
2.3.1. Antioxidant Vitamins. Treatment with the anti-
oxidant vitamins C and E to reduce coronary events
and atherosclerosis progression has been controversial. The
Vitamin E Atherosclerosis Progression Study (VEAPS) [56]
evaluated the eﬀect of vitamin E supplementation in 353
subjects on the change in CIMT. At 3-year follow-up,
vitamin E supplementation failed to reduce the progression
of CIMT (placebo: 0.0023±0.007mm/yr versus vitamin E:
0.0040±0.0007mm/yr; P=.08). The Antioxidant Supple-
mentation in Atherosclerosis Prevention (ASAP) study [57]
evaluated the eﬀect of supplementation with vitamin E plus
slow-releasevitaminConcarotidatheroscleroticprogression
in 520 hypercholesterolemic middle-aged patients. At 6-
year follow-up, supplementation signiﬁcantly reduced the
progression of intima-media thickness by 26% (P=.014).
The antiatherosclerotic eﬀects of antioxidant vitamins
were studied in cardiac transplant patients as well [58,
59]. The study by Fang et al. [59] enrolled 40 cardiac
transplant patients revealed that treatment with antioxidant
vitamins C and E for 1 year retarded the progression
of transplant-associated arteriosclerosis. The intimal index
(plaque area/vessel area) measured by IVUS increased in
the placebo group by 8% but did not change signiﬁcantly
in the treatment group (0.8%; P=.008). These promising
results however, were questioned by Brown et al. [35].Cardiology Research and Practice 9
Table 3: Summary of trials highlighting the anti-atherosclerotic eﬀects of antioxidants.
Study N Medication Imaging modality Follow-up
(months) Outcome Result P-value
SECURE [16] 732 Vitamin E versus
Placebo
B-mode
ultrasound 52 CIMT (mm/yr) 0.0180 versus
0.0174 NS
ASAP [57] 520 Vitamin E + C B-ultrasound 72 CIMT (%) −26 .014¶
Fang et al. [59]4 0 Vitamin E + C
versus Placebo IVUS 12 Δ average intimal
index† (%) +0.8 versus +8 .008
VEAPS [56] 353 Vitamin E versus
Placebo B-ultrasound 36 Δ CIMT (mm/yr)
+0.0040 ±
0.0007 versus
+0.0023 ±
0.0007
.08
Brown et al. [35] 160
Antioxidants versus
Placebo QCA 36 % diameter
stenosis
+1.8 ± 4.2
versus +3.9 ±
5.2
NS
Simvastatin +
Niacin +
antioxidants versus
placebo
+0.7 ± 3.2
versus +3.9 ±
5.2
<.005
Nunes et al. [60]
54
Probucol versus
placebo IVUS
6
Intimal
hyperplasia
volume (mm3)
40.3 ± 26.7
versus 44.8 ±
28.3
.72
% luminal
volume
obstruction
30.4 ± 14.5
versus 30.7 ±
17.2
.86
QCA Restenosis rate
(%) 19.4 versus 18.5 .75
Tardif et al. [61]
305
Probucol versus
placebo IVUS 6 Luminal area @
PCI (mm2)
3.69 ± 2.69
versus 2.66 ±
1.58
<.05
Succinobuccol
(AGI-1067) versus
placebo
3.36 ± 2.12
versus 2.66 ±
1.58
<.05
Tardif et al. [62] 232
280 mg
Succinobuccol
(AGI-1067) versus
placebo
IVUS 12 Plaque volume
(mm3)
−4.0; P =.001¶
versus −0.7;
P = .85
¶
.12‡
¶Baseline versus Followup
† intimal index (plaque area/vessel area)
‡ diﬀerence between groups
In his evaluation of the eﬀect of Simvastatin plus Niacin
with or without antioxidant vitamins versus placebo, he
reported that the regression in average stenosis induced by
Simvastatin-niacin combination was reversed to a progres-
sion with the concomitant use of antioxidants (−0.4% with
simvastatin-niacin alone versus +0.7% with simvastatin-
niacin plus antioxidants; P=.02).
2.3.2. Probucol and AGI-1067. Probucol is an anti-
hyperlipidemic drug that lowers the level of cholesterol
in the bloodstream by increasing the rate of LDL catabolism.
Additionally, probucol may inhibit cholesterol synthesis
and delay cholesterol absorption. Probucol is a powerful
antioxidant as well, which inhibits the oxidation of
cholesterol in LDLs; this slows the formation of foam cells,
which contribute to atherosclerotic plaques. Quantitative
coronaryangiographyandIVUSbased-studiesthatlookedat
probucol’seﬀectonatheromavolumeprogression/regression
revealed varying results [60, 61]. The ﬁrst double-blind
placebo controlled study failed to show a reduction in
neointimal hyperplasia detected by IVUS after 6 months of
treatment with probucol versus placebo (40.3±26.7mm3
versus 44.8±39.3mm3; P=.72) nor in restenosis rate
detected by QCA (probucol: 19.4% versus placebo: 18.5%;
P=.75) [60]. The second study conducted by Tardif et al.
showed an increment in luminal area at PCI site versus
placebo (3.69±2.69mm2 versus 2.66±1.58mm2; P ≤.05)
after 6 months of therapy with probucol on IVUS at the
expense of a signiﬁcant increase in QTc interval (increase
in QTc >60ms: placebo = 4.8% versus probucol = 17.4%;10 Cardiology Research and Practice
Table 4: Summary of trials highlighting the eﬀects of oral hypoglycemic agents and CB1 receptor blockade on atherosclerosis. progression.
Study N Medication Imaging modality Follow-up
(months) Outcome Result P-value
PERISCOPE [68] 543 Pioglitazone versus
Glimipride IVUS 18 Δ PAV (%)
−0.16 versus
+0.73 .002
CHICAGO [69] 462 Pioglitazone versus
Glimipride B-ultrasound 18 Δ CIMT (mm) +0.012 versus
−0.001 .02
STRADUVARIUS [67] 839 CB1-blockade
(Rimonabant) IVUS 18 Δ PAV (%) +0.25 versus
+0.51 .22
Δ total atheroma
volume (mm3)
−2.2 versus
+0.88 .03
P=.02)[61].AGI-1067isametabolicallystablemodiﬁcation
of probucol and an equipotent antioxidant to probucol. In a
1-year, IVUS-based, placebo-controlled trial, AGI-1067 was
shown to cause a trend towards atheroma regression versus
placebo in 232 patients (plaque volume: placebo: −0.4mm3,
P=.85 from baseline versus AGI-1067 −.04mm3, P=.001
from baseline; P=.12 versus placebo) [62]. In the same
study conducted by Tardif above, 280mg of daily AGI-1067
increased luminal area at PCI site versus placebo in a dose
response manner (3.6±2.12mm3 versus 2.66±1.58mm3;
P ≤.05) and did not increase the QTc interval [61].
2.4. Pleiotropic Eﬀects of Other Medications (Table 4)
2.4.1. Cannabinoid Receptor Blockade. CB1 receptors, which
are part of the endocannabinoid (EC) system, are integral
in the metabolism of glucose and lipids. Blockade of this
system causes decreased LDL cholesterol, elevated HDL
cholesterol, decreased systolic blood pressure, decreased
CRP,anddecreasedHbA1c[63–66].Theanti-atherosclerotic
eﬀect of CB1 blockade in abdominally obese patients with
metabolic syndrome and pre-existing coronary disease was
examined in the STRADIVARIUS study [67]. 839 patients
were randomized to placebo or rimonabant 20mg and
underwent IVUS before and after 18 months of their
randomized treatment, 676 patients completed the trial.
There were signiﬁcant reductions in body weight, waist
circumference, triglycerides and C-reactive protein (CRP) in
those treated with rimonabant. In addition, the rimonabant
treated group had a signiﬁcant increase in HDL-cholesterol.
Thestudydidnotdemonstrateaneﬀectonpercentatheroma
volume (increase by 0.25% and 0.51%; P=.22) in the
rimonabantandplacebogroups,respectively.However,itdid
show a favorable eﬀect on total atheroma volume (−2.2mm3
in rimonbant group versus +0.88mm3 in placebo group;
P=.03). However, rimonabant did not demonstrate the
risk/beneﬁt proﬁle that would enable it to be approved by
the food and drug administration (FDA). The increased
risk of neurological and psychiatric side eﬀects—seizures,
depression, anxiety, insomnia, aggressiveness, and more
importantlysuicidalthoughtsamongpatientsrandomizedto
rimonabant warranted this decision.
2.4.2. The Insulin Sensitizers: Thiazolidinediones. The oral
hypoglycemic agent, pioglitazone, has been recently shown
to possess anti-atherosclerotic activity. The Comparison of
pioglitazone versus glimepiride on progression of coro-
nary atherosclerosis in patients with type-2 diabetes; the
PERISCOPE trial [68], randomized 543 patients with CAD
and type-2 diabetes to receive one of the two commonly
prescribed oral hypoglycemic agents, Pioglitazone or Glim-
ipride. IVUS was done at study outset and then repeated
after 18 months of treatment (n=360) to compare the
antiatherosclerotic eﬀects of pioglitazone versus glimipride.
The Change in percent atheroma volume from baseline
increased by 0.73% (95% CI, 0.33% to 1.12%) with
glimepiride and decreased by 0.16% (95% CI, −0.57% to
0.25%) with pioglitazone (P=.002). There was a signiﬁcant
improvementinHbA(1c)levels,HDL,andtriglycerideinthe
pioglitazone versus glimipride group.
The CHICAGO (Carotid Intima-media Thickness in
Atherosclerosis Using Pioglitazone) study evaluated the role
of pioglitazone on the progression of atherosclerosis in the
carotids of 462 patients with type 2 diabetes. The rate of
progression of CIMT was slowed by treatment with piogli-
tazone versus glimipride (−0.001mm versus +0.012mm
respectively; P=.02) at all time points during the 72-week
follow-up period [69].
3. Discussion and Conclusion
The primary interest of cardiovascular researchers in sur-
rogate end points as a proxy for clinical outcomes stems
from the fact that the evaluation of the eﬀect of treatment
on surrogate outcomes is often quicker and requires a
smaller number of patients to demonstrate. The use of these
surrogate endpoints however has been recently criticized
because at the time of FDA approval, information remains
incomplete about idiosyncratic reactions, oﬀ-target eﬀects
or delayed adverse eﬀects. Therefore, the reward of rapid
approval that turn out to be safe and eﬀective needs to be
balanced against harms that might occur later when drugs
approved on the basis of surrogate end points turn out to
have signiﬁcant safety problems or to lack eﬃcacy. Besides,
the clearly recognized inherent limitations of noninvasive
imaging modalities as well as quantitative coronary angiog-
raphy in providing an accurate estimate of plaque burden
can clearly distort the correlation of surrogate endpoints and
clinical outcomes. Among the current imaging modalities,
intravascular ultrasound remains the mainstay technique inCardiology Research and Practice 11
assessing plaque progression/regression because it produces
high quality images of the coronary lumen, vessel wall, and
early atherosclerotic plaques with quantitative identiﬁcation
of all “atheroma components” and is capable of correlating
increments in atheroma volume to future MACE. However,
IVUS remains an invasive imaging modality with limited
access in some catheterization labs and despite the good
quality images it provides, it does not overcome the inherent
limitation of surrogate endpoints and medication-related
adverse events highlighted above. Moreover, the discrepancy
between the results of the conventional IVUS and IVUS
radiofrequency measurements inferred from the aforemen-
tioned “darapladib study,” warrants further research into
which outcome measure to use and which one translates into
adverse clinical outcomes. Therefore, given all the current
limitations in the diﬀerent imaging modalities available to
quantify plaque volume and composition, and the intrinsic
limitations with surrogate endpoints, one should be careful
in applying the results of surrogate endpoint trials in patient
care. Astute cardiovascular researchers are currently using
the available imaging modalities in studying the pleiotropic
eﬀectsofFDA-approvedmedicationsthatpossessgoodsafety
proﬁlethroughtheuseofsurrogateendpointsthatwillhope-
fully translate to beneﬁcial clinical outcomes and add to the
on-label usage of medications (such as pioglitazone use on
top of conventional therapy in diabetic patients with CAD).
Sayingallthat,theuseofsurrogateendpointsinassessingthe
eﬃcacyofnovel pharmacologictherapiesinreducingadverse
clinical cardiovascular outcomes remains controversial.
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